213 related articles for article (PubMed ID: 21352517)
1. Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
Prosperini L; Borriello G; De Giglio L; Leonardi L; Barletta V; Pozzilli C
BMC Neurol; 2011 Feb; 11():26. PubMed ID: 21352517
[TBL] [Abstract][Full Text] [Related]
2. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.
Galassi S; Prosperini L; Logoteta A; Hirsch MN; Fanelli F; De Giglio L; Pozzilli C
Mult Scler Relat Disord; 2016 Jul; 8():99-106. PubMed ID: 27456883
[TBL] [Abstract][Full Text] [Related]
3. From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study.
Prosperini L; Mancinelli CR; Pozzilli C; Grasso MG; Clemenzi A; Collorone S; Pontecorvo S; Francia A; Villani V; Koudriavtseva T; Buttari F; Centonze D; Di Battista G; Frisullo G; Galgani S; Gasperini C
Eur Neurol; 2014; 71(5-6):233-41. PubMed ID: 24480868
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
[TBL] [Abstract][Full Text] [Related]
5. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis.
Prosperini L; Gallo V; Petsas N; Borriello G; Pozzilli C
Eur J Neurol; 2009 Nov; 16(11):1202-9. PubMed ID: 19538207
[TBL] [Abstract][Full Text] [Related]
6. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
7. Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
Prosperini L; Mancinelli C; Haggiag S; Cordioli C; De Giglio L; De Rossi N; Galgani S; Rasia S; Ruggieri S; Tortorella C; Pozzilli C; Gasperini C
J Neurol Neurosurg Psychiatry; 2020 Mar; 91(3):271-277. PubMed ID: 31974130
[TBL] [Abstract][Full Text] [Related]
8. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
Sormani MP; Li DK; Bruzzi P; Stubinski B; Cornelisse P; Rocak S; De Stefano N
Neurology; 2011 Nov; 77(18):1684-90. PubMed ID: 21975200
[TBL] [Abstract][Full Text] [Related]
9. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
10. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.
Prosperini L; Mancinelli CR; De Giglio L; De Angelis F; Barletta V; Pozzilli C
Mult Scler; 2014 Apr; 20(5):566-76. PubMed ID: 23999607
[TBL] [Abstract][Full Text] [Related]
11. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.
Gobbi C; Meier DS; Cotton F; Sintzel M; Leppert D; Guttmann CR; Zecca C
BMC Neurol; 2013 Aug; 13():101. PubMed ID: 23915113
[TBL] [Abstract][Full Text] [Related]
12. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
[TBL] [Abstract][Full Text] [Related]
13. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of responders to interferon therapy for relapsing MS.
Waubant E; Vukusic S; Gignoux L; Dubief FD; Achiti I; Blanc S; Renoux C; Confavreux C
Neurology; 2003 Jul; 61(2):184-9. PubMed ID: 12874396
[TBL] [Abstract][Full Text] [Related]
15. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
[TBL] [Abstract][Full Text] [Related]
16. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
Prosperini L; Giannì C; Leonardi L; De Giglio L; Borriello G; Galgani S; Pozzilli C; Gasperini C
Mult Scler; 2012 Jan; 18(1):64-71. PubMed ID: 21828195
[TBL] [Abstract][Full Text] [Related]
17. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
[TBL] [Abstract][Full Text] [Related]
18. Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.
Baranzini SE; Madireddy LR; Cromer A; D'Antonio M; Lehr L; Beelke M; Farmer P; Battaglini M; Caillier SJ; Stromillo ML; De Stefano N; Monnet E; Cree BA
Mult Scler; 2015 Jun; 21(7):894-904. PubMed ID: 25392319
[TBL] [Abstract][Full Text] [Related]
19. Assessing response to interferon-β in a multicenter dataset of patients with MS.
Sormani MP; Gasperini C; Romeo M; Rio J; Calabrese M; Cocco E; Enzingher C; Fazekas F; Filippi M; Gallo A; Kappos L; Marrosu MG; Martinelli V; Prosperini L; Rocca MA; Rovira A; Sprenger T; Stromillo ML; Tedeschi G; Tintorè M; Tortorella C; Trojano M; Montalban X; Pozzilli C; Comi G; De Stefano N;
Neurology; 2016 Jul; 87(2):134-40. PubMed ID: 27306626
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]